

LOST EXPRESSION, FOUND FAMILIES: HOW IHC REVEALS LYNCH SYNDROME BEYOND AGE AND FAMILY HISTORY

Stefano Realdon

UEG Week Berlin 2025

Poster

Colorectal

October 4, 2025

A single-center study of 101 Lynch syndrome patients found that universal immunohistochemistry screening identifies affected families missed by traditional clinical criteria, particularly those with later-onset cancers and MSH6 or PMS2 mutations.

KEY POINTS

- Index cases identified through immunohistochemistry on tumor samples had a mean age of 57.93 years at genetic diagnosis compared to 46.35 years for those identified by Amsterdam II or revised Bethesda clinical criteria.
- Half of the index patients diagnosed through immunohistochemistry did not meet Amsterdam II criteria and would have been missed by clinical criteria alone.
- Patients with pathogenic variants in MSH6 and PMS2 genes, which have lower penetrance and later cancer onset, represented 50 percent of the immunohistochemistry group versus only 5 percent of the clinical criteria group.
- Universal immunohistochemistry screening detects mismatch repair-deficient tumors in patients diagnosed later in life and those without evident family history of cancer.
- The findings support applying immunohistochemistry screening for mismatch repair protein loss in both colorectal and endometrial cancers to identify Lynch syndrome families.

VIEW THIS CONTENT ON GUTFLIX

<https://gutflix.eu/search/d/bdfaca50-a814-11f0-bc2b-0242ac140006>



AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.